Osteoporosis Treatment with Boniva in Elderly Patients

Introduction to Osteoporosis Treatment

The American College of Rheumatology strongly recommends against osteoporosis medications in low-risk patients due to known harms without evidence of benefit 3, 4

Bone mineral density (BMD) measurement with DXA scan is required to establish T-score, and FRAX calculation is necessary to determine the 10-year risk of major osteoporotic fracture and hip fracture 1, 2
History of prior fragility fractures, particularly spine, hip, wrist, or humerus, is an essential factor in determining the risk category 1, 2
Vertebral fracture assessment (VFA) or spinal x-ray is necessary to identify asymptomatic vertebral fractures 1, 2
Evaluation for secondary causes of osteoporosis and falls risk is crucial before initiating treatment 1, 2

Boniva is appropriate for patients with prior osteoporotic fracture(s), BMD T-score ≤ -3.5, or FRAX 10-year risk: major osteoporotic fracture ≥30% OR hip fracture ≥4.5% 1, 2
The American College of Rheumatology recommends Boniva for patients with high risk of fracture, defined as BMD T-score between -2.5 and -3.5 or FRAX 10-year risk: major osteoporotic fracture 20-30% OR hip fracture 3-4.5% 1, 2

All patients starting Boniva must receive calcium 1,000-1,200 mg daily and vitamin D 600-800 IU daily, with target serum 25(OH)D level ≥30 ng/mL 1, 2, 5, 7

Check serum creatinine and calculate creatinine clearance before starting Boniva, and monitor proteinuria and renal function during treatment 7
Intravenous bisphosphonates are generally not recommended if creatinine clearance <30 mL/min 7
Perform dental examination before starting treatment, and complete necessary invasive dental procedures before initiating therapy 7

BMD with VFA or spinal x-ray should be monitored every 1-2 years during therapy, and continue monitoring every 1-2 years after discontinuation 1, 2
Reassess fracture risk after 3-5 years to determine the need for continued therapy 6

Consider alternative agents instead of Boniva if the patient has very high risk with prior fracture, glucocorticoid-induced osteoporosis at very high risk, or cannot tolerate oral bisphosphonates 3, 4, 8, 9

Do not start treatment without risk stratification, as treating low-risk patients exposes them to unnecessary harm 3, 4
Do not forget calcium and vitamin D supplementation, as these are essential components of osteoporosis treatment 1, 2, 5, 6